8:00 am Check-In & Coffee Networking
8:55 am Chair’s Opening Remarks
8:57 am
Evaluating Factors Impacting Immunogenicity & Dosing to Navigate Safety Concerns
9:00 am Exploring the Benefits of Direct Administration to Lower Dose & Cost
Synopsis
- Evaluating systemic and direct routes of administration for vector therapy
- Outlining the workflow to implement direct administration for CNS indications
- Elevating the safety and cost benefits of direct administration
9:30 am Understanding Immunosuppression for AAV Vectors to Improve Safety
Synopsis
- Exploring modifications to AAV vectors which facilitate immune suppression
- Emphasizing how strategies to eliminate immunogenicity improve vector efficacy
- Highlighting how immunosuppression can also enable a reduction in dose
10:00 am Morning Break & Networking
Revolutionizing Vector Production for Maximum Impact
11:00 am Round Table: Enhancing Vector Manufacturing to Improve Quality & Cut Costs
Synopsis
- Demonstrating how reproducible manufacturing processes can improve vector production
- Highlighting the need to produce high quality vectors to lower doses and enhance safety
- Emphasizing the importance of improved quality and quantity vectors to reduce costs
12:00 pm Lonza | Expertise Partner Presentation
12:30 pm Lunch Break & Networking
Harnessing Learnings From AAV Vectors to Progress Other Vector Therapies
1:30 pm Rethinking Vector Choice: Utilizing Optimized HSV to Enhance Safety & Efficacy
Synopsis
- Reflecting on the lack of efficient tissue targeting impacting AAV vector development
- Demonstrating that HSV vectors have excellent cellular tropism biodistribution shedding characteristics with regional administration
- Highlighting how regional administration minimizes off-target effects, improves safety, efficacy, and limits immunogenicity
2:00 pm Leveraging Parvovirus Vectors to Combat Immunogenicity, Off-Target Effects, & Limited Payload Capacity
Synopsis
- Highlighting how selecting a vector with limited pre-existing human immunity and excellent tissue tropism improves vector efficacy and safety
- Exploring the benefits of additional cargo space to treat a wider range of indications
- Consolidating learnings and regulations from AAV vectors to facilitate parvovirus vector development
2:30 pm Afternoon Break & Networking
Strategically Injecting Capital into Gene Therapy Vectors
3:00 pm Panel Discussion: Advancing Gene Therapy Vectors with More Insightful Investment
Synopsis
- Discussing the importance of investment into the gene therapy vector space to characterize attractive investment prospects
- Refocusing investment strategies to primarily propel vector therapy innovation
- Determining how workflows and mindsets from the antibody therapy space may hinder vector therapies from reaching their potential